Efficacy of an adjuvanted herpes zoster subunit vaccine when given with a quadrivalent seasonal influenza vaccine

January 09, 2018

Share article

The authors were interested in the immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when given together with a quadrivalent seasonal inactivated influenza vaccine (IIV4). They performed a phase 3, open-label, randomised clinical trial in adults aged ≥50 years who were randomised (1:1) to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant System) and IIV4 at day 0 followed by a second HZ/su dose at month 2 (coadministration group), or IIV4 at month 0 and HZ/su at months 2 and 4 (control group). 413 participants were vaccinated in the coadministration group and 415 in the control group. The authors found that the HZ/su vaccine response rate in the coadministration group was 95.8% and the anti-glycoprotein E GMC[Control/Coadmin] ratio was 1.08 (95%CI 0.97-1.20). Therefore noninferiority of HZ/su and IIV4 antibody responses compared with controls is demonstrated. There was no interference in the immune responses to either vaccine when the vaccine was coadministered.

Read more here

Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, et al. ISSN: J Infect Dis; 216(11): 1352-1361


Added: January 09, 2018